Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone

Bone

Volumn 50, Issue 1, 2012, Pages 237-244

  Schneider, Marlon R ^a   Dahlhoff, Maik ^a   Andrukhova, Olena ^b   Grill, Jessica ^a   Glösmann, Martin ^b   Schüler, Christiane ^b   Weber, Karin ^a   Wolf, Eckhard ^a   Erben, Reinhold G ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

EGFR; Mutant mice; Osteocalcin; PTH

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOCALCIN; PARATHYROID HORMONE;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE TURNOVER; CANCELLOUS BONE; CELL ISOLATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; HORMONE ACTION; LUMBAR VERTEBRA; METAPHYSIS; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; WILD TYPE;

ANABOLIC AGENTS; ANIMALS; BONE AND BONES; BONE DENSITY; FEMALE; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCALCIN; PARATHYROID HORMONE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; X-RAY MICROTOMOGRAPHY;

EID: 81255164917     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.019     Document Type: Article

References (36)

1. Brown E.M. Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 1993, 2:541-551.
2. Poole K.E., Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005, 5:612-617.
3. Hodsman A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
4. Juppner H., Abou-Samra A.B., Freeman M., Kong X.F., Schipani E., Richards J., et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991, 254:1024-1026.
5. Swarthout J.T., D'Alonzo R.C., Selvamurugan N., Partridge N.C. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 2002, 282:1-17.
6. Miyakoshi N., Kasukawa Y., Linkhart T.A., Baylink D.J., Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 2001, 142:4349-4356.
7. Demiralp B., Chen H.L., Koh A.J., Keller E.T., McCauley L.K. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 2002, 143:4038-4047.
8. Onyia J.E., Helvering L.M., Gelbert L., Wei T., Huang S., Chen P., et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem 2005, 95:403-418.
9. Raggatt L.J., Qin L., Tamasi J., Jefcoat S.C., Shimizu E., Selvamurugan N., et al. Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J Biol Chem 2008, 283:6790-6798.
10. Bouxsein M.L., Pierroz D.D., Glatt V., Goddard D.S., Cavat F., Rizzoli R., et al. Beta-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J Bone Miner Res 2005, 20:635-643.
11. Kramer I., Keller H., Leupin O., Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism?. Trends Endocrinol Metab 2010, 21:237-244.
12. Qin L., Qiu P., Wang L., Li X., Swarthout J.T., Soteropoulos P., et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 2003, 278:19723-19731.
13. von Stechow D., Zurakowski D., Pettit A.R., Muller R., Gronowicz G., Chorev M., et al. Differential transcriptional effects of PTH and estrogen during anabolic bone formation. J Cell Biochem 2004, 93:476-490.
14. Li X., Liu H., Qin L., Tamasi J., Bergenstock M., Shapses S., et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 2007, 282:33086-33097.
15. Koh A.J., Demiralp B., Neiva K.G., Hooten J., Nohutcu R.M., Shim H., et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 2005, 146:4584-4596.
16. Li X., Qin L., Bergenstock M., Bevelock L.M., Novack D.V., Partridge N.C. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem 2007, 282:33098-33106.
17. Schneider M.R., Sibilia M., Erben R.G. The EGFR network in bone biology and pathology. Trends Endocrinol Metab 2009, 20:517-524.
18. Drake M.T., Baldassare J.J., McConkey C.L., Gonzalez E.A., Martin K.J. Parathyroid hormone increases the expression of receptors for epidermal growth factor in UMR 106-01 cells. Endocrinology 1994, 134:1733-1737.
19. Gonzalez E.A., Martin K.J. Retinoids modulate the effect of PTH and calcitriol on EGF receptor expression in UMR 106-01 cells. Calcif Tissue Int 1996, 58:429-434.
20. Gonzalez E.A., Disthabanchong S., Kowalewski R., Martin K.J. Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells. Kidney Int 2002, 61:1627-1634.
21. Ahmed I., Gesty-Palmer D., Drezner M.K., Luttrell L.M. Transactivation of the epidermal growth factor receptor mediates parathyroid hormone and prostaglandin F2 alpha-stimulated mitogen-activated protein kinase activation in cultured transgenic murine osteoblasts. Mol Endocrinol 2003, 17:1607-1621.
22. Qin L., Tamasi J., Raggatt L., Li X., Feyen J.H., Lee D.C., et al. Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. J Biol Chem 2005, 280:3974-3981.
23. Schneider M.R., Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009, 218:460-466.
24. Threadgill D.W., Dlugosz A.A., Hansen L.A., Tennenbaum T., Lichti U., Yee D., et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995, 269:230-234.
25. Sibilia M., Wagner E.F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 1995, 269:234-238.
26. Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A., Werb Z., et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995, 376:337-341.
27. Lee D., Cross S.H., Strunk K.E., Morgan J.E., Bailey C.L., Jackson I.J., et al. Wa5 is a novel ENU-induced antimorphic allele of the epidermal growth factor receptor. Mamm Genome 2004, 15:525-536.
28. Schneider M.R., Mayer-Roenne B., Dahlhoff M., Proell V., Weber K., Wolf E., et al. High cortical bone mass phenotype in betacellulin transgenic mice is EGFR-dependent. J Bone Miner Res 2009, 24:455-467.
29. Erben R.G. Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 1997, 45:307-313.
30. Hofbauer L.C., Zeitz U., Schoppet M., Skalicky M., Schuler C., Stolina M., et al. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. Arthritis Rheum 2009, 60:1427-1437.
31. Wong G., Cohn D.V. Separation of parathyroid hormone and calcitonin-sensitive cells from non-responsive bone cells. Nature 1974, 252:713-715.
32. Genther Williams S.M., Disbrow G.L., Schlegel R., Lee D., Threadgill D.W., Lambert P.F. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res 2005, 65:6534-6542.
33. Zhang X., Tamasi J., Lu X., Zhu J., Chen H., Tian X., et al. Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo. J Bone Miner Res 2011, 26:1022-1034.
34. Xian C.J. Roles of epidermal growth factor family in the regulation of postnatal somatic growth. Endocr Rev 2007, 28:284-296.
35. Yao G.Q., Wu J.J., Troiano N., Insogna K. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab 2011, 29:141-148.
36. Ferrari S.L., Pierroz D.D., Glatt V., Goddard D.S., Bianchi E.N., Lin F.T., et al. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. Endocrinology 2005, 146:1854-1862.